The present disclosure relates to a recombinant nucleic acid molecule based on point mutation of translation initiation element and use thereof in the preparation of circular RNA, and in particular to a recombinant nucleic acid molecule for preparing circular RNA, a recombinant expression vector, circular RNA, a composition, a method for preparing circular RNA, a method for expressing a target polypeptide in a cell, a method for preventing or treating a disease, a method for editing a translation initiation element sequence, and a system for editing a translation initiation element sequence. The recombinant nucleic acid molecule provided by the present disclosure provides a novel Clean PIE system for the in vitro preparation of circular RNA, which can avoid introducing additional exon sequences into circular RNA, improve sequence accuracy of circular RNA molecules, reduce changes in a secondary structure of circular RNA, and then reduce immunogenicity of circular RNA, and has a good application prospect in the fields of nucleic acid vaccines, expression of therapeutic proteins, gene therapy, etc.

Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.

Provided herein in are armed Seneca Valley Viruses which have been altered to carry a therapeutic payload, i.e. to encode an agent for treating cancer. These armed Seneca Valley Viruses are oncolytic and express a cancer treating agent. Also provided herein are compositions and methods of using an armed Seneca Valley Virus to treat cancer in a subject.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

A Senecavirus A polypeptide generally includes at least a portion of 151-434 of SEQ ID NO:1, amino acids 435-673 of SEQ ID NO:1, or amino acids 674-937 of SEQ ID NO:1. The Senecavirus A polypeptide may be used as a capture antigen in a method or device for detecting antibody that specifically binds to the Senecavirus A polypeptide. The Senecavirus A polypeptide may be used as a immunogen to vaccinate a subject having or at risk of having a Senecavirus A infection.

The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding one or more inhibitory nucleic acids targeting SCNA or a portion thereof, TMEM106B or a portion thereof, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.

A trivalent transgene that encodes a viral surface glycoprotein component, a viral nucleoprotein component and a viral RNA polymerase component is provided. Vaccines incorporating the trivalent transgene are also provided, along with methods of vaccinating mammals to protect against viral infection.

A T-cell epitope polypeptide of Senecavirus A (SVA) having an amino acid sequence represented by one of SEQ ID NOs: 1-7: SEQ ID NO: 1:

TABLE-US-00001 DEALGRVLTPAAVDEALVDL; SEQIDNO:2: AILAKLGLALAAVTPGLIIL; SEQIDNO:3: KASPVLQYQL; SEQIDNO:4: EMKKLGPVAL; SEQIDNO:5: AHDAFMAGSG; SEQIDNO:6: PPLGDDQIEYLQVLKSLALT; and SEQIDNO:7: LASTLIAQAVSKRLYGSQSV.

The present disclosure relates to a novel regulatory element for enhancing RNA stability or mRNA translation; ZCCHC2 interacting with the regulatory element; and uses thereof. Being capable of increasing the expression of a target protein, the novel regulatory element for enhancing RNA stability or mRNA translation; and ZCCHC2 interacting with regulatory element according to the present disclosure are applicable in various fields, depending on the uses of the target protein.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.